Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

Background: Bimiralisib is a balanced dual panPI3K/mTOR inhibitor, which demonstrated anti-cancer activity in a number of preclinical models. Pharmacokinetic (PK) data suggested that intermittent targeting of the PI3K/mTOR pathway could be preferable to continuous daily dosing. Preclinical models in squamous cell head and neck cancer (SCCHN) demonstrated that NOTCH1 Loss of Function (LoF) mutations were associated with efficacy of bimiralisib...